Search

Author/Creator Belonosova, Elena

1. Dolutegravir-based Antiretroviral Therapy for Patients Coinfected With Tuberculosis and Human Immunodeficiency Virus: A Multicenter, Noncomparative, Open-label, Randomized Trial. (28th March 2019)

Authors:
Dooley, Kelly E; Kaplan, Richard; Mwelase, Noluthando; Grinsztejn, Beatriz; Ticona, Eduardo; Lacerda, Marcus; Sued, Omar; Belonosova, Elena; Ait-Khaled, Mounir; Angelis, Konstantinos; Brown, Dannae; Singh, Rajendra; Talarico, Christine L; Tenorio, Allan R; Keegan, Michael R; Aboud, Michael
Journal:
Clinical infectious diseases
Issue:
Volume 70:Number 4(2020)
Page Start:
549
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study. Issue 12 (December 2017)

Authors:
Orrell, Catherine; Hagins, Debbie P; Belonosova, Elena; Porteiro, Norma; Walmsley, Sharon; Falcó, Vicenç; Man, Choy Y; Aylott, Alicia; Buchanan, Ann M; Wynne, Brian; Vavro, Cindy; Aboud, Michael; Smith, Kimberly Y
Journal:
Lancet
Issue:
Volume 4:Issue 12(2017)
Page Start:
e536
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study. Issue 11 (November 2021)

Authors:
Orkin, Chloe; Bernal Morell, Enrique; Tan, Darrell H S; Katner, Harold; Stellbrink, Hans-Jürgen; Belonosova, Elena; DeMoor, Rebecca; Griffith, Sandy; Thiagarajah, Shanker; Van Solingen-Ristea, Rodica; Ford, Susan L; Crauwels, Herta; Patel, Parul; Cutrell, Amy; Smith, Kimberly Y; Vandermeulen, Kat...
Journal:
Lancet
Issue:
Volume 8:Issue 11(2021)
Page Start:
e668
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Issue 11 (November 2021)

Authors:
Jaeger, Hans; Overton, Edgar T; Richmond, Gary; Rizzardini, Giuliano; Andrade-Villanueva, Jaime Federico; Mngqibisa, Rosie; Hermida, Antonio Ocampo; Thalme, Anders; Belonosova, Elena; Ajana, Faïza; Benn, Paul D; Wang, Yuanyuan; Hudson, Krischan J; Español, Carlos Martín; Ford, Susan L; Crauwels, ...
Journal:
Lancet
Issue:
Volume 8:Issue 11(2021)
Page Start:
e679
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗